MERCURYLABPharmaceuticals
Mercury Labs — Cash Flow Statement
₹860.00
+0.00%
Mercury Labs Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -5.04 Cr | 1.95 Cr | 1.40 Cr | 3.27 Cr | — |
| Capital Expenditure | -9.04 Cr | -6.27 Cr | -1.06 Cr | -1.91 Cr | — |
| End Cash Position | 2.19 Cr | 8.23 Cr | 7.32 Cr | 6.93 Cr | — |
| Beginning Cash Position | 8.23 Cr | 7.32 Cr | 6.93 Cr | 4.87 Cr | — |
| Changes In Cash | -6.03 Cr | 0.91 Cr | 0.38 Cr | 2.07 Cr | — |
| Financing Cash Flow | -0.99 Cr | -1.04 Cr | -1.01 Cr | -1.23 Cr | — |
| Net Other Financing Charges | 0.08 Cr | 0.04 Cr | -0.08 Cr | -0.18 Cr | — |
| Interest Paid Cff | -0.55 Cr | -0.38 Cr | -0.36 Cr | -0.45 Cr | — |
| Cash Dividends Paid | -0.42 Cr | -0.42 Cr | -0.42 Cr | -0.24 Cr | — |
| Net Issuance Payments Of Debt | -1.40 Cr | 0.13 Cr | 0.22 Cr | -1.21 Cr | — |
| Net Short Term Debt Issuance | -1.58 Cr | -0.31 Cr | 0.29 Cr | -0.15 Cr | — |
| Net Long Term Debt Issuance | 0.18 Cr | 0.44 Cr | -0.06 Cr | -1.06 Cr | — |
| Investing Cash Flow | -9.04 Cr | -6.27 Cr | -1.06 Cr | -1.89 Cr | — |
| Dividends Received Cfi | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Investment Purchase And Sale | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -9.04 Cr | -6.27 Cr | -1.06 Cr | -1.89 Cr | — |
| Sale Of PPE | 0.00 | 0.00 | 0.00 | 0.02 Cr | — |
| Purchase Of PPE | -9.04 Cr | -6.27 Cr | -1.06 Cr | -1.91 Cr | — |
| Operating Cash Flow | 4.00 Cr | 8.23 Cr | 2.45 Cr | 5.19 Cr | — |
| Taxes Refund Paid | -2.39 Cr | -1.26 Cr | -1.10 Cr | -1.91 Cr | — |
| Interest Paid Cfo | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Change In Working Capital | -1.75 Cr | -0.64 Cr | -6.73 Cr | -0.80 Cr | — |
| Change In Other Current Liabilities | -0.70 Cr | 0.16 Cr | -0.09 Cr | -36000.00 | — |
| Change In Other Current Assets | -0.88 Cr | 0.19 Cr | -1.37 Cr | 0.48 Cr | — |
| Change In Payable | 4.64 Cr | -1.20 Cr | -0.48 Cr | -4.92 Cr | — |
| Change In Inventory | -1.00 Cr | 0.70 Cr | -0.12 Cr | -1.62 Cr | — |
| Change In Receivables | -3.89 Cr | -0.49 Cr | -4.62 Cr | 4.99 Cr | — |
| Other Non Cash Items | 0.55 Cr | 0.38 Cr | 0.36 Cr | 0.45 Cr | — |
| Depreciation And Amortization | 2.88 Cr | 2.82 Cr | 2.48 Cr | 2.45 Cr | — |
| Depreciation | 2.88 Cr | 2.82 Cr | 2.46 Cr | 2.45 Cr | — |
| Gain Loss On Investment Securities | 0.05 Cr | — | — | -0.02 Cr | — |
| Net Income From Continuing Operations | 4.66 Cr | 6.92 Cr | 7.44 Cr | 5.03 Cr | — |
| Amortization Cash Flow | — | 0.02 Cr | 0.02 Cr | — | — |
| Sale Of Investment | — | — | 0.00 | 0.00 | 0.00 |
| Purchase Of Investment | — | — | 0.00 | 0.00 | 0.00 |
| Other Cash Adjustment Outside Changein Cash | — | — | — | 1000.00 | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Mercury Labs
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.